System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective
Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a childr...
Gespeichert in:
Veröffentlicht in: | Clinical therapeutics 2012-06, Vol.34 (6), p.1459-1465 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1465 |
---|---|
container_issue | 6 |
container_start_page | 1459 |
container_title | Clinical therapeutics |
container_volume | 34 |
creator | Nichols, Kristen R., PharmD, BCPS Knoderer, Chad A., PharmD Cox, Elaine G., MD Kays, Michael B., PharmD, FCCP |
description | Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times. |
doi_str_mv | 10.1016/j.clinthera.2012.05.005 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020508701</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291812003232</els_id><sourcerecordid>2747491841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-bc0a93888d8b8107f4dfa7067f52cefe69ccbb5304ba5b5b20c066a7414811f83</originalsourceid><addsrcrecordid>eNqNks9u1DAQxiMEokvhFcASQnDJduzE-dMDUrV06UqVqLRdwc1ynEnrJXGC7a1In4jHxNEurdQT8sE-_Oabz_NNFL2jMKdAs5PtXLXa-Fu0cs6AsjnwOQB_Fs1okZcxpemP59EMaFrGrKTFUfTKuS0AJCVnL6MjxjKeM57Moj_r0Xns4u-6RrLqhhY7NF563RvSNyR0IBuH01Macv7bo6mxjlem2bkJudJDsKB0G9ycXMv7vpLKy4586Z02N2TtrfR4M56SJUqnK91qP05iGx-e9_s2S9t3RJLFrW5ri-ajIxe9G7SXLblC6wZUXt_h6-hFI1uHbw73cbRZnl8vLuLLb19Xi7PLWPEk8XGlQJZJURR1URUU8iatG5lDljecKWwwK5WqKp5AWkle8YqBgiyTeUrTgtKmSI6jT3vdwfa_dui86LRT2LbSYL9zggIDDkUONKDvn6DbfmdNcBeoJMuSEtJJMN9TyvbOWWzEYHUn7RggMYUptuIhTDGFKYCLEGaofHvQ31Ud1g91_9ILwIcDIJ2SbWOlUdo9chnQvGSThbM9h2FwdxqtcEqjUVhrG6Yr6l7_h5nPTzQmToe2P3FE9_hz4UKNWE-7N60eZWHrWDh_AVBG2MY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1036639048</pqid></control><display><type>article</type><title>System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Nichols, Kristen R., PharmD, BCPS ; Knoderer, Chad A., PharmD ; Cox, Elaine G., MD ; Kays, Michael B., PharmD, FCCP</creator><creatorcontrib>Nichols, Kristen R., PharmD, BCPS ; Knoderer, Chad A., PharmD ; Cox, Elaine G., MD ; Kays, Michael B., PharmD, FCCP</creatorcontrib><description>Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2012.05.005</identifier><identifier>PMID: 22657253</identifier><language>eng</language><publisher>Bridgewater, NJ: Elsevier Inc</publisher><subject>Adolescent ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Antimicrobial agents ; Bacteria ; Bacterial infections ; Biological and medical sciences ; Child ; Child, Preschool ; Children & youth ; Drug stores ; extended infusion ; Feasibility Studies ; Female ; Hospitals ; Hospitals, Pediatric ; Humans ; Infant ; Internal Medicine ; Male ; Medical Education ; Medical sciences ; Monte Carlo simulation ; Mortality ; Nursing ; pediatric ; Pediatrics ; Penicillanic Acid - administration & dosage ; Penicillanic Acid - analogs & derivatives ; Penicillanic Acid - therapeutic use ; Pharmacology. Drug treatments ; Piperacillin - administration & dosage ; Piperacillin - therapeutic use ; piperacillin-tazobactam</subject><ispartof>Clinical therapeutics, 2012-06, Vol.34 (6), p.1459-1465</ispartof><rights>Elsevier HS Journals, Inc.</rights><rights>2012 Elsevier HS Journals, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-bc0a93888d8b8107f4dfa7067f52cefe69ccbb5304ba5b5b20c066a7414811f83</citedby><cites>FETCH-LOGICAL-c533t-bc0a93888d8b8107f4dfa7067f52cefe69ccbb5304ba5b5b20c066a7414811f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1036639048?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26017928$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22657253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nichols, Kristen R., PharmD, BCPS</creatorcontrib><creatorcontrib>Knoderer, Chad A., PharmD</creatorcontrib><creatorcontrib>Cox, Elaine G., MD</creatorcontrib><creatorcontrib>Kays, Michael B., PharmD, FCCP</creatorcontrib><title>System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.</description><subject>Adolescent</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antimicrobial agents</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children & youth</subject><subject>Drug stores</subject><subject>extended infusion</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Hospitals</subject><subject>Hospitals, Pediatric</subject><subject>Humans</subject><subject>Infant</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical Education</subject><subject>Medical sciences</subject><subject>Monte Carlo simulation</subject><subject>Mortality</subject><subject>Nursing</subject><subject>pediatric</subject><subject>Pediatrics</subject><subject>Penicillanic Acid - administration & dosage</subject><subject>Penicillanic Acid - analogs & derivatives</subject><subject>Penicillanic Acid - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperacillin - administration & dosage</subject><subject>Piperacillin - therapeutic use</subject><subject>piperacillin-tazobactam</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNks9u1DAQxiMEokvhFcASQnDJduzE-dMDUrV06UqVqLRdwc1ynEnrJXGC7a1In4jHxNEurdQT8sE-_Oabz_NNFL2jMKdAs5PtXLXa-Fu0cs6AsjnwOQB_Fs1okZcxpemP59EMaFrGrKTFUfTKuS0AJCVnL6MjxjKeM57Moj_r0Xns4u-6RrLqhhY7NF563RvSNyR0IBuH01Macv7bo6mxjlem2bkJudJDsKB0G9ycXMv7vpLKy4586Z02N2TtrfR4M56SJUqnK91qP05iGx-e9_s2S9t3RJLFrW5ri-ajIxe9G7SXLblC6wZUXt_h6-hFI1uHbw73cbRZnl8vLuLLb19Xi7PLWPEk8XGlQJZJURR1URUU8iatG5lDljecKWwwK5WqKp5AWkle8YqBgiyTeUrTgtKmSI6jT3vdwfa_dui86LRT2LbSYL9zggIDDkUONKDvn6DbfmdNcBeoJMuSEtJJMN9TyvbOWWzEYHUn7RggMYUptuIhTDGFKYCLEGaofHvQ31Ud1g91_9ILwIcDIJ2SbWOlUdo9chnQvGSThbM9h2FwdxqtcEqjUVhrG6Yr6l7_h5nPTzQmToe2P3FE9_hz4UKNWE-7N60eZWHrWDh_AVBG2MY</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Nichols, Kristen R., PharmD, BCPS</creator><creator>Knoderer, Chad A., PharmD</creator><creator>Cox, Elaine G., MD</creator><creator>Kays, Michael B., PharmD, FCCP</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective</title><author>Nichols, Kristen R., PharmD, BCPS ; Knoderer, Chad A., PharmD ; Cox, Elaine G., MD ; Kays, Michael B., PharmD, FCCP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-bc0a93888d8b8107f4dfa7067f52cefe69ccbb5304ba5b5b20c066a7414811f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antimicrobial agents</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children & youth</topic><topic>Drug stores</topic><topic>extended infusion</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Hospitals</topic><topic>Hospitals, Pediatric</topic><topic>Humans</topic><topic>Infant</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical Education</topic><topic>Medical sciences</topic><topic>Monte Carlo simulation</topic><topic>Mortality</topic><topic>Nursing</topic><topic>pediatric</topic><topic>Pediatrics</topic><topic>Penicillanic Acid - administration & dosage</topic><topic>Penicillanic Acid - analogs & derivatives</topic><topic>Penicillanic Acid - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperacillin - administration & dosage</topic><topic>Piperacillin - therapeutic use</topic><topic>piperacillin-tazobactam</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nichols, Kristen R., PharmD, BCPS</creatorcontrib><creatorcontrib>Knoderer, Chad A., PharmD</creatorcontrib><creatorcontrib>Cox, Elaine G., MD</creatorcontrib><creatorcontrib>Kays, Michael B., PharmD, FCCP</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nichols, Kristen R., PharmD, BCPS</au><au>Knoderer, Chad A., PharmD</au><au>Cox, Elaine G., MD</au><au>Kays, Michael B., PharmD, FCCP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>34</volume><issue>6</issue><spage>1459</spage><epage>1465</epage><pages>1459-1465</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.</abstract><cop>Bridgewater, NJ</cop><pub>Elsevier Inc</pub><pmid>22657253</pmid><doi>10.1016/j.clinthera.2012.05.005</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0149-2918 |
ispartof | Clinical therapeutics, 2012-06, Vol.34 (6), p.1459-1465 |
issn | 0149-2918 1879-114X |
language | eng |
recordid | cdi_proquest_miscellaneous_1020508701 |
source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
subjects | Adolescent Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Antimicrobial agents Bacteria Bacterial infections Biological and medical sciences Child Child, Preschool Children & youth Drug stores extended infusion Feasibility Studies Female Hospitals Hospitals, Pediatric Humans Infant Internal Medicine Male Medical Education Medical sciences Monte Carlo simulation Mortality Nursing pediatric Pediatrics Penicillanic Acid - administration & dosage Penicillanic Acid - analogs & derivatives Penicillanic Acid - therapeutic use Pharmacology. Drug treatments Piperacillin - administration & dosage Piperacillin - therapeutic use piperacillin-tazobactam |
title | System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A31%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=System-Wide%20Implementation%20of%20the%20Use%20of%20an%20Extended-Infusion%20Piperacillin/Tazobactam%20Dosing%20Strategy:%20Feasibility%20of%20Utilization%20From%20a%20Children's%20Hospital%20Perspective&rft.jtitle=Clinical%20therapeutics&rft.au=Nichols,%20Kristen%20R.,%20PharmD,%20BCPS&rft.date=2012-06-01&rft.volume=34&rft.issue=6&rft.spage=1459&rft.epage=1465&rft.pages=1459-1465&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2012.05.005&rft_dat=%3Cproquest_cross%3E2747491841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1036639048&rft_id=info:pmid/22657253&rft_els_id=S0149291812003232&rfr_iscdi=true |